Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Novavax Expects Full Year 2024 Revenue Of $800M-$1B Versus Consensus Of $969.56M, With Combined R&D and SG&A Expenses Of $700M-$800M

Author: Benzinga Newsdesk | February 28, 2024 09:09am

Posted In: NVAX